Inflammatory Process, Neurodegenation and Novel Treatment in Mental Disorders: Study Demonstrations with Memantine and Dextromethorphan

精神疾患之免疫學、神經退化性與新治療方式：Memantine與Dextromethorphan的研究報告

陸汝斌(Ru-Band Lu)；李聖玉(Sheng-Yu Lee)；陳秀蘭(Shiou-Lan Chen)；張芸瑄(Yun-Hsuan Chang)

神經性退化 ； 免疫學 ； 精神疾病 ； 治療 ； inflammation ； mental disorder ； neurodegeneration ； treatment

台灣精神醫學

27卷4期（2013 / 12 / 01）

276 - 282+2

英文

1970年，治療精神疾病的藥物有突破性研發，但至1990年代起，精神藥物研發呈現停滯狀態。可能是基因與遺傳因素占疾病的絕大部分，卻無法改變；而精神疾病精神病理機制機轉所知有限。此外，精神疾病之神經性退化情形涉入程度，限制了精神疾病藥物的發展，如精神分裂症，雙極疾患，藥物濫用，焦慮症，人格疾患等。從其具一定程度社會功能障礙與腦萎縮現象，可推測這些主要精神性疾病具神經性退化的特質。利用memantine及dextromethorphan的抗發炎及神經細胞保護作用的功能，我們已完成了一些針對精神疾病治療性的動物及人體臨床試驗。因此，由免疫的角度初探，可給予臨床工作者進一步了解主要精神疾病的退化情形以及研擬新的治療方式。

Since 1970s, psychotropic medications had been remarkably developed. But only limited brand-new drugs have come out of the market since 1990s. Limiting the development of new psychotropic agents has three reasons: high loading of genetic component in major mental illnesses, the pathogeneses of major mental illness still being unknown, and the involvement of neurodegeneration in major mental illnesses. In other words, the high level of social impairment and chronic deteriorating course suggest that many mental illnesses have neurodegenerative characteristics. Using memantine and dextromethorphan for their anti-imflmmatory and neuroprotective benefits, we have done some animal and human studies. This overview focusing on the data of those two agents, is intended to help clinicians and researchers have new thoughts of psychiatric disorders and better idea to develop better treatment.

1. Barcia, C,de Pablos, V,Bautista-Hernandez, V(2005).Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration.Parkinsonism Relat Disord,11,435-9.
2. Beyer, JL,Krishnan, KR(2002).Volumetric brain imaging findings in mood disorders.Bipolar Disord,4,89-104.
3. Chen, SL,Lee, SY,Chang, YH(2012).Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.J Neuroimmune Pharmacol,7,656-64.
4. Chen, SL,Lee, SY,Tao, PL(2012).Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment.J Neuroimmune Pharmacol,7,1025-33.
5. Chen, SL,Tao, PL,Chu, CH(2012).Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats.J Neuroimmune Pharmacol,7,444-53.
6. Chipana, C,Torres, I,Camarasa, J,Pubill, D,Escubedo, E(2008).Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents.Neuropharmacology,54,1254-63.
7. De Peri, L,Crescini, A,Deste, G,Fusar-Poli, P,Sacchetti, E,Vita, A(2012).Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies.Curr Pharm Des,18,486-94.
8. Drevets, WC,Price, JL,Simpson, JR, Jr.(1997).Subgenual prefrontal cortex abnormalities in mood disorders.Nature,386,824-7.
9. Horstmann, S,Binder, EB(2009).Pharmacogenomics of antidepressant drugs.Pharmacol Ther,124,57-73.
10. Kato, M,Serretti, A(2010).Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Mol Psychiatry,15,473-500.
11. Kempton, MJ,Geddes, JR,Ettinger, U,Williams, SC,Grasby, PM(2008).Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder.Arch Gen Psychiatry,65,1017-32.
12. Largen, JW, Jr.,Smith, RC,Calderon, M(1984).Abnormalities of brain structure and density in schizophrenia.Biol Psychiatry,19,991-1013.
13. Lee, SY,Chen, SL,Chang, YH(2012).The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder.J Affect Disord,138,295-300.
14. Lee, SY,Chen, SL,Chang, YH(2013).Genotype variant associated with add-on memantine in bipolar II disorder.Int J Neuropsychopharmacol,1-9.
15. Lee, SY,Chen, SL,Chang, YH(2013).Add-on memantinememantine to valproate treatment increased HDL-C in bipolar II disorder.J Psychiatr Res,47,1343-8.
16. Li, L,Lu, G,Yao, H,Zhao, Y,Feng, Z,Yew, DT(2005).Postmortem changes in the central nervous system and adrenal medulla of the heroin addicts.Int J Neurosci,115,1443-9.
17. Liu, B,Hong, JS(2003).Primary rat mesencephalic neuronglia, neuron-enriched, microglia-enriched, and astroglia-enriched cultures.Methods Mol Med,79,387-95.
18. Liu, L,Jia, F,Yuan, G(2010).Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semiquantitative analysis.Psychiatry Res,176,1-7.
19. Malhotra, AK,Murphy, GM, Jr.,Kennedy, JL(2004).Pharmacogenetics of psychotropic drug response.Am J Psychiatry,161,780-96.
20. Parsons, CG,Danysz, W,Quack, G(1999).Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data.Neuropharmacology,38,735-67.
21. Popik, P,Skolnick, P(1996).The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence.Pharmacol Biochem Behav,53,791-7.
22. Ribeiro Do Couto, B,Aguilar, MA,Manzanedo, C,Rodriguez-Arias, M,Minarro, J(2004).Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice.Prog Neuropsychopharmacol Biol Psychiatry,28,1035-43.
23. Sklair-Tavron, L,Shi, WX,Lane, SB,Harris, HW,Bunney, BS,Nestler, EJ(1996).Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons.Proc Natl Acad Sci U S A,93,11202-7.
24. Stoll, AL,Renshaw, PF,Yurgelun-Todd, DA,Cohen, BM(2000).Neuroimaging in bipolar disorder: what have we learned?.Biol Psychiatry,48,505-17.
25. Wang, SC,Chou, DT,Wallenstein, MC(1977).Studies on the potency of various antitussive agents.Agents Actions,7,337-40.
26. Wu, HM,Tzeng, NS,Qian, L(2009).Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-infl ammation by preventing microglial activation.Neuropsychopharmacology,34,2344-57.
27. Zhang, W,Qin, L,Wang, T(2005).3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.FASEB J,19,395-7.
28. Zhang, W,Wang, T,Qin, L(2004).Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.FASEB J,18,589-91.